Apogee Therapeutics (APGE) experienced a significant 5.18% drop in its stock price during pre-market trading on Monday, despite announcing positive results from its Phase 2 APEX clinical trial for APG777, its experimental treatment for moderate-to-severe atopic dermatitis.

The company reported that Part A of the Phase 2 trial met all primary and key secondary endpoints, with APG777 demonstrating a 71.0% decrease from baseline in the Eczema Area and Severity Index (EASI) at Week 16, compared to 33.8% for placebo. Additionally, 66.9% of participants treated with APG777 achieved EASI-75, which the company claims is the highest topline and placebo-adjusted efficacy of any biologic in a global study for atopic dermatitis.

Despite these encouraging results, which would typically drive a stock price increase, Apogee Therapeutics' shares unexpectedly declined. This counterintuitive market reaction could be due to various factors, such as profit-taking by early investors, broader market conditions, or concerns about the drug's future development and commercialization prospects. The disconnect between positive clinical news and negative stock performance underscores the complex dynamics often at play in biotech stock valuations.